Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study

Hae Jin Kim; Young Sik Kim; Chang Beom Lee; Moon Gi Choi; Hyuk Jae Chang; Soo Kyoung Kim; Jae Myung Yu; Tae Ho Kim; Ji Hyun Lee; Kyu Jeung Ahn; Kyung Wan Min; Eun Jung Kyung; Yeo Kyeong Kim; Kwan Woo Lee

doi:10.1007/s13300-021-01148-1

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study

Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon Gi Choi, Hyuk Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min, Eun Jung Kyung, Yeo Kyeong Kim, Kwan Woo Lee

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Introduction: The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods: Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results: At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p < 0.0001); in addition, 56.3, 60.3, and 62.3% of patients, respectively, achieved decreases in HbA1c of at least 0.3%, and 40.1, 46.5, and 52.4% of patients, respectively, achieved decreases in HbA1c of at least 0.5%. The proportion of the patient population achieving HbA1c < 7.0% increased throughout the study period, reaching 30.4, 35.4, and 36.9% at weeks 12, 24, and 52, respectively; at these same time points, the percentage of patients achieving HbA1c < 6.5% increased to 9.5, 11.9, and 13.2% of the total study population. FPG levels and lipid parameters were also significantly decreased after teneligliptin treatment. There were no significant safety concerns. Conclusion: Our results suggest the significant glucose-lowering effect of teneligliptin after switching from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic control was maintained for up to 52 weeks without safety concerns.

Original language	English
Pages (from-to)	2907-2920
Number of pages	14
Journal	Diabetes Therapy
Volume	12
Issue number	11
DOIs	https://doi.org/10.1007/s13300-021-01148-1
Publication status	Published - 2021 Nov

Bibliographical note

Funding Information:
Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.

Funding Information:
The authors thank the investigators and the participants of the study. Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. HJK and KWL contributed to the design and conduct of the study and the acquisition, analysis, and interpretation of data, and drafted the manuscript. YSK, CBL, M-GC, H-JC, SKK, JMY, THK, JHL, KJA, and KWM contributed to the conduct of the study and the interpretation of data. EJK and YKK contributed to the design of the study and analysis of data. All authors reviewed and approved the final manuscript. Eun Jung Kyung and Yeo Kyeong Kim are employees of Handok Inc. Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min and Kwan Woo Lee have nothing to disclose. All patients provided written informed consent before being enrolled in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional review board of each center or by the local institutional review board (IRB), including Ajou University Hospital IRB (AJIRB-MED-OBS-15-410) (a full list of participating centers is provided in ESM Table S2). The datasets generated and/or analyzed during this study are available from the corresponding author on reasonable request.

Publisher Copyright:
© 2021, The Author(s).

All Science Journal Classification (ASJC) codes

Internal Medicine
Endocrinology, Diabetes and Metabolism

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s13300-021-01148-1

Cite this

Kim, H. J., Kim, Y. S., Lee, C. B., Choi, M. G., Chang, H. J., Kim, S. K., Yu, J. M., Kim, T. H., Lee, J. H., Ahn, K. J., Min, K. W., Kyung, E. J., Kim, Y. K., & Lee, K. W. (2021). Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. Diabetes Therapy, 12(11), 2907-2920. https://doi.org/10.1007/s13300-021-01148-1

@article{89dca547812647d895af3358cfd53802,

title = "Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study",

abstract = "Introduction: The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods: Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results: At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p < 0.0001); in addition, 56.3, 60.3, and 62.3% of patients, respectively, achieved decreases in HbA1c of at least 0.3%, and 40.1, 46.5, and 52.4% of patients, respectively, achieved decreases in HbA1c of at least 0.5%. The proportion of the patient population achieving HbA1c < 7.0% increased throughout the study period, reaching 30.4, 35.4, and 36.9% at weeks 12, 24, and 52, respectively; at these same time points, the percentage of patients achieving HbA1c < 6.5% increased to 9.5, 11.9, and 13.2% of the total study population. FPG levels and lipid parameters were also significantly decreased after teneligliptin treatment. There were no significant safety concerns. Conclusion: Our results suggest the significant glucose-lowering effect of teneligliptin after switching from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic control was maintained for up to 52 weeks without safety concerns.",

author = "Kim, {Hae Jin} and Kim, {Young Sik} and Lee, {Chang Beom} and Choi, {Moon Gi} and Chang, {Hyuk Jae} and Kim, {Soo Kyoung} and Yu, {Jae Myung} and Kim, {Tae Ho} and Lee, {Ji Hyun} and Ahn, {Kyu Jeung} and Min, {Kyung Wan} and Kyung, {Eun Jung} and Kim, {Yeo Kyeong} and Lee, {Kwan Woo}",

note = "Funding Information: Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Funding Information: The authors thank the investigators and the participants of the study. Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. HJK and KWL contributed to the design and conduct of the study and the acquisition, analysis, and interpretation of data, and drafted the manuscript. YSK, CBL, M-GC, H-JC, SKK, JMY, THK, JHL, KJA, and KWM contributed to the conduct of the study and the interpretation of data. EJK and YKK contributed to the design of the study and analysis of data. All authors reviewed and approved the final manuscript. Eun Jung Kyung and Yeo Kyeong Kim are employees of Handok Inc. Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min and Kwan Woo Lee have nothing to disclose. All patients provided written informed consent before being enrolled in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional review board of each center or by the local institutional review board (IRB), including Ajou University Hospital IRB (AJIRB-MED-OBS-15-410) (a full list of participating centers is provided in ESM Table S2). The datasets generated and/or analyzed during this study are available from the corresponding author on reasonable request. Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = nov,

doi = "10.1007/s13300-021-01148-1",

language = "English",

volume = "12",

pages = "2907--2920",

journal = "Diabetes Therapy",

issn = "1869-6953",

publisher = "Springer Publishing Company",

number = "11",

}

Kim, HJ, Kim, YS, Lee, CB, Choi, MG, Chang, HJ, Kim, SK, Yu, JM, Kim, TH, Lee, JH, Ahn, KJ, Min, KW, Kyung, EJ, Kim, YK & Lee, KW 2021, 'Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study', Diabetes Therapy, vol. 12, no. 11, pp. 2907-2920. https://doi.org/10.1007/s13300-021-01148-1

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study. / Kim, Hae Jin; Kim, Young Sik; Lee, Chang Beom et al.
In: Diabetes Therapy, Vol. 12, No. 11, 11.2021, p. 2907-2920.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors

T2 - 52-Week Results from a Prospective Observational Study

AU - Kim, Hae Jin

AU - Kim, Young Sik

AU - Lee, Chang Beom

AU - Choi, Moon Gi

AU - Chang, Hyuk Jae

AU - Kim, Soo Kyoung

AU - Yu, Jae Myung

AU - Kim, Tae Ho

AU - Lee, Ji Hyun

AU - Ahn, Kyu Jeung

AU - Min, Kyung Wan

AU - Kyung, Eun Jung

AU - Kim, Yeo Kyeong

AU - Lee, Kwan Woo

N1 - Funding Information: Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. Funding Information: The authors thank the investigators and the participants of the study. Sponsorship for this study and the Rapid Service Fee were funded by Handok Inc., Seoul, Republic of Korea. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. HJK and KWL contributed to the design and conduct of the study and the acquisition, analysis, and interpretation of data, and drafted the manuscript. YSK, CBL, M-GC, H-JC, SKK, JMY, THK, JHL, KJA, and KWM contributed to the conduct of the study and the interpretation of data. EJK and YKK contributed to the design of the study and analysis of data. All authors reviewed and approved the final manuscript. Eun Jung Kyung and Yeo Kyeong Kim are employees of Handok Inc. Hae Jin Kim, Young Sik Kim, Chang Beom Lee, Moon-Gi Choi, Hyuk-Jae Chang, Soo Kyoung Kim, Jae Myung Yu, Tae Ho Kim, Ji Hyun Lee, Kyu Jeung Ahn, Kyung Wan Min and Kwan Woo Lee have nothing to disclose. All patients provided written informed consent before being enrolled in the study. The study was conducted in accordance with the Declaration of Helsinki, and the protocol was approved by the institutional review board of each center or by the local institutional review board (IRB), including Ajou University Hospital IRB (AJIRB-MED-OBS-15-410) (a full list of participating centers is provided in ESM Table S2). The datasets generated and/or analyzed during this study are available from the corresponding author on reasonable request. Publisher Copyright: © 2021, The Author(s).

PY - 2021/11

Y1 - 2021/11

N2 - Introduction: The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods: Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results: At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p < 0.0001); in addition, 56.3, 60.3, and 62.3% of patients, respectively, achieved decreases in HbA1c of at least 0.3%, and 40.1, 46.5, and 52.4% of patients, respectively, achieved decreases in HbA1c of at least 0.5%. The proportion of the patient population achieving HbA1c < 7.0% increased throughout the study period, reaching 30.4, 35.4, and 36.9% at weeks 12, 24, and 52, respectively; at these same time points, the percentage of patients achieving HbA1c < 6.5% increased to 9.5, 11.9, and 13.2% of the total study population. FPG levels and lipid parameters were also significantly decreased after teneligliptin treatment. There were no significant safety concerns. Conclusion: Our results suggest the significant glucose-lowering effect of teneligliptin after switching from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic control was maintained for up to 52 weeks without safety concerns.

AB - Introduction: The aim of this study was to assess the efficacy and safety of switching to teneligliptin from other dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM) inadequately controlled despite treatment with a stable dose of other DPP-4 inhibitors. Methods: Patients with glycosylated hemoglobin (HbA1c) ≥ 7% despite taking DPP-4 inhibitors other than teneligliptin, with or without other antidiabetic agents, for at least 3 months were enrolled in this study. Patients on DPP-4 inhibitors administered prior to participation in this study were switched to 20 mg teneligliptin once daily and the dose was maintained for the 52-week study period. The primary endpoint was the change in HbA1c at week 12. Fasting plasma glucose (FPG) and the blood lipid profile were also evaluated. Adverse events were monitored for safety assessment. Results: At weeks 12, 24, and 52, the HbA1c values significantly decreased by − 0.39, − 0.44, and − 0.52%, respectively, compared to the baseline value (p < 0.0001); in addition, 56.3, 60.3, and 62.3% of patients, respectively, achieved decreases in HbA1c of at least 0.3%, and 40.1, 46.5, and 52.4% of patients, respectively, achieved decreases in HbA1c of at least 0.5%. The proportion of the patient population achieving HbA1c < 7.0% increased throughout the study period, reaching 30.4, 35.4, and 36.9% at weeks 12, 24, and 52, respectively; at these same time points, the percentage of patients achieving HbA1c < 6.5% increased to 9.5, 11.9, and 13.2% of the total study population. FPG levels and lipid parameters were also significantly decreased after teneligliptin treatment. There were no significant safety concerns. Conclusion: Our results suggest the significant glucose-lowering effect of teneligliptin after switching from other DPP-4 inhibitors in patients with T2DM. The improvement in glycemic control was maintained for up to 52 weeks without safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=85115163085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85115163085&partnerID=8YFLogxK

U2 - 10.1007/s13300-021-01148-1

DO - 10.1007/s13300-021-01148-1

M3 - Article

AN - SCOPUS:85115163085

SN - 1869-6953

VL - 12

SP - 2907

EP - 2920

JO - Diabetes Therapy

JF - Diabetes Therapy

IS - 11

ER -

Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this